title: The extracellular domain of p75NTR is necessary to inhibit neurotrophin-3 signaling through TrkA.
abstract: The TrkA receptor is activated primarily by nerve growth factor (NGF), but it can also be activated by high concentrations of neurotrophin 3 (NT-3). The pan-neurotrophin receptor p75(NTR) strongly inhibits activation of TrkA by NT-3 but not by NGF. To examine the role of p75(NTR) in regulating the specificity of TrkA signaling, we expressed both receptors in Xenopus oocytes. Application of NGF or NT-3 to oocytes expressing TrkA alone resulted in efflux of (45)Ca(2+) by a phospholipase C-gamma-dependent pathway. Coexpression of p75(NTR) with TrkA inhibited (45)Ca(2+) efflux in response to NT-3 but not NGF. The inhibitory effect on NT-3 activation of TrkA increased with increasing expression of p75(NTR). Coexpression of a truncated p75(NTR) receptor lacking all but the first 9 amino acids of the cytoplasmic domain inhibited NT-3 stimulation of (45)Ca(2+) efflux, whereas coexpression of an epidermal growth factor receptor/p75(NTR) chimera (extracellular domain of epidermal growth factor receptor with transmembrane and cytoplasmic domains of p75(NTR)) did not inhibit NT-3 signaling through TrkA. These studies demonstrated that the extracellular domain of p75(NTR) was necessary to inhibit NT-3 signaling through TrkA. Remarkably, p75(NTR) binding to NT-3 was not required to prevent signaling through TrkA, since occupying p75(NTR) with brain-derived neurotrophic factor or anti-p75 antibody (REX) did not rescue the ability of NT-3 to activate (45)Ca(2+) efflux. These data suggested a physical association between TrkA and p75(NTR). Documenting this physical interaction, we showed that p75(NTR) and TrkA could be coimmunoprecipitated from Xenopus oocytes. Our results suggest that the interaction of these two receptors on the cell surface mediated the inhibition of NT-3-activated signaling through TrkA.
authors.affiliation: Departments of Pathology and Laboratory Medicine, UCLA, Los Angeles, California 90095-1732, USA. pmischel@mednet.ucla.edu
authors.forename: P S
authors.initials: PS
authors.lastname: Mischel
authors.forename: S G
authors.initials: SG
authors.lastname: Smith
authors.forename: E R
authors.initials: ER
authors.lastname: Vining
authors.forename: J S
authors.initials: JS
authors.lastname: Valletta
authors.forename: W C
authors.initials: WC
authors.lastname: Mobley
authors.forename: L F
authors.initials: LF
authors.lastname: Reichardt
mesh_terms: D000818:Animals; D006801:Humans; D020933:Neurotrophin 3 / Q000737:chemistry / Q000378:metabolism*; D020800:Receptor, Nerve Growth Factor; D020917:Receptor, trkA / Q000737:chemistry / Q000378:metabolism*; D017475:Receptors, Nerve Growth Factor / Q000737:chemistry / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D015398:Signal Transduction; D014982:Xenopus laevis
chemical_list: D020933:Neurotrophin 3; D020800:Receptor, Nerve Growth Factor; D017475:Receptors, Nerve Growth Factor; D011994:Recombinant Proteins; D020917:Receptor, trkA